49). Median followup was 8.6 = 0.5 months.
Results: The 6-month actuarial patient survival was 95%, 92% in the double therapy group and 98% in the triple therapy group (not significant). The 6-month actuarial graft survival was 88%, 84% in the double therapy group and 92% in the triple therapy group (not significant). The overall incidence of rejection and steroid resistant rejection was 34.2 and 4.2%, respectively. There was a strong trend toward less rejection in the mycophenolate mofetil group than in the double therapy group (26.2 versus 42.4%), Crossover was common, and was 42.6% from triple to double therapy and 18.6% from double to triple therapy. The reasons for discontinuation of mycophenolate mofetil were gastrointestinal toxicity, primarily diarrhea, or less commonly hematological toxicity, primarily neutropenia or thrombocytopenia. Gastrointestinal toxicity was ameliorated by separating the doses oftacrolimus and mycophenolate mofetil by 2 to 4 hours, and reducing the dose to 1 gm. daily.
Conclusions: Mycophenolate mofetil appears to be a useful third agent with tacrolimus in patients undergoing renal transplantation, and is associated with a reduction in the rate of rejection and a low incidence of steroid resistant rejection. There is a high incidence of gastrointestinal toxicity associated with the 2 gm. daily dose but this complication is relatively straightforward to manage.
KEy WORDS: prednisone, kidney transplantation, drug therapy Although renal transplantation under tacrolimus based immunosuppression has been associated with excellent short and medium-term outcomes,1-7 some of the earlier studies, particularly those not using induction antilymphocyte preparations, have described relatively high rates of early acute rejection ranging from 50 to 60%. [8] [9] [10] [11] [12] While the majority of these rejection episodes have been steroid responsive, patients with steroid resistant rejection have had markedly inferior outcomes with a 3-year actuarial graft survival of 53%.2 An early study which looked at azathioprine as a third agent demonstrated a modest reduction in the incidence of rejection and steroid resistant rejection from 55 to 45% and 14 to 8%, respectively.1.2 Unfortunately, overall graft survival was not improved, and was actually worse at 3 years in patients not receiving azathioprine (76 versus 84% of patients randomized to double therapy). 2.3 having been evaluated in 3 large prospective, randomized trials with cyclosporine based immunosuppression.1 3 -1 6 In these trials the incidence of early acute rejection was reduced significantly from 41 to 17 to 20%, although the I-year patient and graft survival rates were unaffected. In an attempt to determine whether mycophenolate mofetil would offer similar benefits with tacrolimus based therapy, we began a prospective, randomized trial of tacrolimus and prednisone with and without mycophenolate mofetil in adult renal transplant recipients. Azathioprine was not used in the control group because of the inferior outcomes noted in an earlier randomized trial,2·3 In this initial report we evaluate the first year of the trial with a relatively short followup, since as yet there are no clinical reports on the combination oftacrolimus and mycophenolate mofetil in a randomized trial. Immunosuppression. A dose of 0.15 mg./kg. tacrolimus was given orally to all patients preoperatively. In the recovery roo~ or intensive care unit 0.025 to 0.05 mg./kg./24 hours intravenous tacrolimus was given as a continuous infusion. Wher patients were able to tolerate oral medications 0.15 mg./kg. tacrolimus orally tv.;ce a day was begun and intravenous tacrolimus was tapered off in 0 to 48 hours. Further dosage adjustments were guided by levels. Target tacrolimus levels by whole blood IMx, were 20 to 25 ng./ml., for the first 2 weeks, 15 to 20 at 1 month, 10 to 15 at 3 months and 5 to 12 chronically.
PATIENTS AND METHODS

A new
Steroids. All patients received intraoperatively 1,000 mg. methylprednisolone intravenously and a short steroid taper from 200 to 20 or 30 mg. daily for 6 days. Further tapering was individualized but in the ideal case the prednisone dose was decreased to 15 mg. daily by 3 to 4 weeks and then by 2.5 mg. decrements to 10 mg. daily by 2 to 3 months after transplantation. Thereafter the prednisone dose was decreased by 2.5 mg. every 4 to 6 weeks until it was completely discontinued, if possible.
Mycophenolate mofetil. Patients randomized to receive mycophenolate mofetil were given 1,000 mg. orally preoperatively and started on 1,000 mg. orally twice a day beginning on postoperative day 1. After the first few months of the study tacrolimus and mycophenolate mofetil dosages were separated by 3 to 4 hours, which significantly improved the tolerability of the combination of the 2 agents. In the case of adverse events, for example diarrhea, gastritis, leukopenia or thrombocytopenia, the mycophenolate mofetil dose was generally decreased to 500 mg. orally twice a day. If side effects persisted, mycophenolate mofetil was discontinued.
Rejection. More than 95% of rejection episodes were biopsy proved and routinely treated with a steroid bolus (1,000 mg. intravenous methylprednisolone) and short recycle with augmentation of the tacrolimus dosage. For steroid resistant rejection 5 mg. OKT3 was given intravenously daily for 10 to 14 days. Patients randomized to double therapy were crossed over to receive mycophenolate mofetil if moderate acute or steroid resistant rejection developed. Sporadically, 500 mg) kg. immunoglobulin x 4 was administered intravenously for refractory rejection, 17. 18 that is in patients who had persistent rejection despite steroids, OKT3 and crossover to mycophenolate mofetil.
Randomization and statistical analysis. Continuous variables are presented as mean plus or minus standard deviation and categorical variables as proportions. Randomization was done by sequential draw of assignment using a variable block randomization scheme. 19 The block sizes varied (4 or 6) and were selected with equal probability. The order of assignment within a block was determined by generating a random number between 0 and 1, and then rearranging the random numbers in ascending order. Baseline characteristics of the patient population were compared using the standard 2-sample t test for continuous data and Pearson's chi-square test for categorical data.
Patient survival was calculated from the date of kidney transplantation until death and graft survival from the date of kidney transplantation until graft failure, re-transplantation or patient death. Survival curves were generated using the Kaplan-Meier (product limit) method 20 and compared by the log rank (Mantel-Cox) test. 21 All analyses were performed according to intention to treat using computer software. All tests were 2-tailed and p <0.05 was considered statistically significant. Although no investigational agents were used, approval by the Health Sciences Institutional Review Board of the University of Pittsburgh was obtained with yearly renewal because of the randomized nature of the trial.
RESULTS
Median followup was 8.6 months, which was too short to allow for calculation of I-year actuarial patient and graft survival statistics. The 6-month actuarial patient survival was 95%, 92% in the double therapy group and 98% in the triple therapy group (not significant). The 6-month actuarial graft survival was 88%, 84% in the double therapy group and 92% in the triple therapy group (not significant). The overall incidence of rejection and steroid resistant rejection was 34.2 and 4.2%, respectively (table 2). There was a strong trend toward less rejection in the mycophenolate mofetil group than in the double therapy group 126.2 versus 42.4%). There was also a trend toward less steroid resistant rejection in the mycopheno~ate mofetil group (1.6 versus 6.8%), In the patients who never discontinued mycophenolate mofetil the incidences of rejection and steroid resistant rejection were 14 and 0%, respectively (table 3). The incidence of asymptomatic or symptomatic cytomegalovirus was 12.5%, and was higher in the mycophenolate mofetil group than in the double therapy group 09.7 versus 5.1%, p <0.03, table 2). Cytomegalovirus was treated with intravenous ganciclovir and reduction of immunosuppression until the antigenemia level decreased to zero. There were no serious cytomegalovirus related complications. Prophylatic high dose oral acyclovir was given to seropositive recipients. Seronegative recipients of seropositive organs received either ganciclovir and cytomegalovirus hyperimmune globulin or no prophylaxis with frequent antigenemia screening as part of a separate randomized trial.
Post-transplantation lymphoproliferative disorder occurred in a 57-year-old sensitized woman who was randomized to double therapy but received OKT3 and mycophenolate mofetil on postoperative day 1 because of suspected antibody mediated rejection. She eventually achieved normal renal n:ncti~n but multiple nodules of pulmonary lymphoproliferatlVe dIsorder developed 9 months after transplantation. She was treated with cessation of tacrolimus and mycophenolate mofetil, intravenous ganciclovir and lymphokine activated killer cell therapy,22 with regression of the lesions and initially stable renal function. The patient returned to dialysis 3 months later.
There was no significant difference between the 2 groups in delayed graft function (25%, table 2) or initial posttransplantation diabetes (9.6%), which was lower than that reported in earlier trials. 1.6. 7 The routine management of this latter complication has involved gradual reduction of the tacrolimus and prednisone dosages. Historicallv 50% of our patients have been able to discontinue insulin 'after the decrease in dosage. I Followup was too short to determine the final incidence of post· transplantation diabetes in this series.
Crossover between the 2 groups was common. In 42.6% of patients randomized to triple therapy mycophenolate mofetil was discontinued at 1 time or another (table 2). The most common reason was gastrointestinal toxicity, principally diarrhea. and occasionally gastritis. which was believed to be related to mycophenolate mofetil because it was generally not seen in patients randomized to double therapy. Hematological toxicity, principally neutropenia or thrombocytopenia, was another cause of crossover. Viral infection with cytomegalovirus, Epstein-Barr virus or polyoma (BK) virus was the other main indication for crossover. Even in the absence of crossover reduction of the mycophenolate mofehl dose to 500 mg. orally twice a day was common, mainly for gastrointestinal toxicity. The incidence of crossover declined from the first to the second 6 months of the trial from 48.5 to 35.7%. Mycophenolate mofetil was added because of rejection III 18.6% of patients randomized to double therapy.
DISCUSSION
We have used tacrolimus as a primary immunosuppressive agent in our patients undergoing renal transplantation since 1989, and have been impressed with the overall immunosuppressive efficacy, improved half-life, ability to allow steroid withdrawal in the majority of patients with successful transplants, lower cholesterol levels and lower incidence ofhypertension. 1 -12 However, the incidence of early acute rejection in our patients, who have not as a rule received induction antilymphocyte therapy, has been relatively high.s-12 The consequences of steroid resistant rejection have been frankly disappointing.2•3 Thus, we have considered possible third agents with the goal of reducing the rate of rejection, and possibly improving overall patient and graft survival. Although azathioprine was associated with somewhat less rejection, the overall poorer outcomes associated with its use rendered it a poor candidate for routine use as a third agent.2.3 Antilymphocyte induction has not been used routinely in our program because of concerns about over immunosuppression. In view of the favorable outcomes achieved vvith mycophenolate mofetil and cyclosporine based regimens,13-16 we thought that it would be worthwhile to evaluate mycophenolate mofetil with tacrolimus.
The preliminary findings suggest that a lower incidence of rejection is achievable with mycophenolate mofetil, and with a greater accrual of patients we would expect to see a statis· tically significant reduction in rejection. The gastrointestinal a?d hematological complications seem not to be excessively dIfIic~lt to manage. Separating the timing of the 2 agents and reducmg the dosage of mycophenolate mofetil have usually been successful: and the rate of crossover from triple to double therapy m the second 6 months of the trial was less tha~ in the first 6 months. The higher incidence of cytomegalOVIrus IS of some concern but the explanation may be that the 5. ~ % incidence of cytomegalovirus in the double therapy group IS perhaps unusually low, rather than the incidence in the triple therapy group being particularly high. Of note, our overall preliminary findings are similar to those of Roth et aI, who have reported their retrospective, nonrandomized experience with tacrolimus and mycophenolate mofetil. 23 They have reported even less rejection in patients receiving myconphenolate mofetil (8 versus 21% of patients not receiving myconphenolate mofetill presumably because of the routine use of antibody induction.
In conclusion, we are encouraged by the combination of tacrolimus and mycophenolate mofetil, and expect that the associated toxicities will be manageable, in return for a substantial reduction in the incidence of acute rejection. Longer followup will be necessary to determine whether there will be an improvement in patient or graft survival.
Regina Fenton, Loraine Oczypok. Deborah Good. Holly Woods, Jareen Flohr, Sue Bauder, Jennifer Ovesney, Sharon Orlofske. Mark Paynter, and Gerri James assisted with pa- forward to manage." a significant consequence of gastrointestinal toxicity is inadequate absorption of medications and. thus. suboptimal immunosuppression. perhaps contributing to greater rejection risk. The authors noted that the trend towards less rejection was not significant. Unfortunately. these preliminary findings may not have the statistical power to offer definitive conclusions. Finally. the relatively low graft survival noted in a short followup (gold standard for followup is I-year graft survival) is of major concern, since graft loss at 1 year should be predictably greater.
Nevertheless, this study offers a large experience with the use of tacrolimus and mycophenolate mofetil although the data are difficult to assess and it is too soon to deri\'e assumptions. It is apparent that mycophenolate mofetil and tacrolimus compared to mycophenolate mofetil and cyclosporine 2 are associated with greater gastrointestinal toxicity and cytomegalovirus infections. Whether this difference justifies the possibility of better acute rejection prevention remains to be seen. I agree with the authors that longer followup is necessary. 
